Literature DB >> 10788031

Radiologic tests after a new diagnosis of breast cancer.

R O Dillman1, S Chico.   

Abstract

CONTEXT: Radiologic tests may be overused in the staging of newly diagnosed breast cancer.
OBJECTIVE: To determine the frequency with which radiologic tests are used in women with newly diagnosed breast cancer and the yield of such tests in these patients.
METHODS: We used the tumor registry database from the Hoag Cancer Center, Newport Beach, California, to identify and classify the disease stage of all patients with breast cancer who received a diagnosis from or were initially treated by Hoag staff from 1990 to 1994. After excluding patients with unknown tumor (T) and lymph node (N) status, we retrospectively determined the frequency with which radiologic tests were performed within 4 weeks of diagnosis and the proportion of these tests that detected metastatic disease.
RESULTS: A total of 1910 radiologic tests, including 646 bone scans, 637 chest radiographs, and 627 other tests, were obtained in 1167 patients with a known TN status. Radiologic tests were performed in 42% of patients with carcinoma in situ, but none of the 183 tests detected metastases. Eight hundred twenty-eight radiologic tests were performed in patients who were classified as having stage I disease on the basis of TN criteria. Only three of these tests (0.4%) detected metastatic disease, and all three were performed in one patient with bone pain. For patients who were classified as having stage IIA, stage IIB, or stage III disease on the basis of TN criteria, 5 of 410 tests (1.2%), 20 of 294 tests (6.8%), and 33 of 195 tests (17%), respectively, yielded positive results.
CONCLUSIONS: Radiologic staging tests are overused in patients with newly diagnosed, early-stage breast cancer. These tests are unnecessary in patients with breast cancer who have 1) a tumor that is 5 cm in diameter or smaller, 2) no axillary lymphadenopathy on physical examination, 3) normal results on blood chemistry tests, and 4) no symptoms or physical findings of metastatic disease.

Entities:  

Mesh:

Year:  2000        PMID: 10788031

Source DB:  PubMed          Journal:  Eff Clin Pract        ISSN: 1099-8128


  6 in total

1.  Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer.

Authors:  Naoki Niikura; Jun Liu; Colleen M Costelloe; Shana L Palla; John E Madewell; Naoki Hayashi; Tse-Kuan Yu; Yutaka Tokuda; Richard L Theriault; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Oncologist       Date:  2011-05-31

2.  Use of imaging for staging of early-stage breast cancer in two integrated health care systems: adherence with a choosing wisely recommendation.

Authors:  Erin E Hahn; Tania Tang; Janet S Lee; Corrine Munoz-Plaza; Joyce O Adesina; Ernest Shen; Braden Rowley; Jared L Maeda; David M Mosen; John C Ruckdeschel; Michael K Gould
Journal:  J Oncol Pract       Date:  2015-04-21       Impact factor: 3.840

3.  Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer.

Authors:  Brittany L Bychkovsky; Hao Guo; Jazmine Sutton; Laura Spring; Jennifer Faig; Ibiayi Dagogo-Jack; Chiara Battelli; Mary Jane Houlihan; Tsai-Chu Yeh; Steven E Come; Nancy U Lin
Journal:  Oncologist       Date:  2016-08-22

4.  Patient perceptions and expectations regarding imaging for metastatic disease in early stage breast cancer.

Authors:  Demetrios Simos; Brian Hutton; Ian D Graham; Angel Arnaout; Jean-Michel Caudrelier; Sasha Mazzarello; Mark Clemons
Journal:  Springerplus       Date:  2014-04-05

5.  Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments.

Authors:  Paul Andreas Compare Cloos; Stephan Christgau; Nina Lyubimova; Jean-Jacques Body; Per Qvist; Claus Christiansen
Journal:  Breast Cancer Res       Date:  2003-05-19       Impact factor: 6.466

6.  Staging Investigations in Breast Cancer: Collective Opinion of UK Breast Surgeons.

Authors:  N Chand; R I Cutress; R S Oeppen; A Agrawal
Journal:  Int J Breast Cancer       Date:  2013-11-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.